Breast Cancer, Colon Cancer, Medullary Thyroid Cancer, Non Small Cell Lung Cancer, Other Solid Tumors With Evidence of Activating RET Alteration, Pancreatic Cancer, Papillary Thyroid Cancer
Conditions
Brief summary
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed description
N/A for expanded access
Interventions
DRUGSelpercatinib
Open-label expanded access
Sponsors
Eli Lilly and Company
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib * Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy * Have adequate organ function
Exclusion criteria
* Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor * Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Countries
Australia, France, Germany, Hong Kong, Israel, Italy, Japan, New Zealand, Poland, Singapore, Spain, Switzerland, United States
Outcome results
None listed